Overview: Von Willebrand Factor Collagen Binding TestIntroduction: The Von Willebrand Factor Collagen Binding Test measures vWF collagen binding to diagnose von Willebrand disease, causing bruising. Following 2023 ASH guidelines, it uses coagulation methods for high specificity, supporting coagulation screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in coagulation for patients with suspected von Willebrand disease.
Other Names: vWF:CB Assay, Von Willebrand Collagen Binding Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: vWF collagen binding testing began in the 1990s with bleeding disorder research. Coagulation methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures vWF collagen binding activity to diagnose von Willebrand disease, guides treatment, and evaluates patients with bruising.
Test Parameters: 1. vWF Collagen Binding Activity
Pretest Condition: No fasting required. Collect citrated plasma. Report history of bruising or coagulation disorders.
Specimen: Citrated Plasma (NaCit, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bruising, bleeding, or history of coagulation disorders. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, von Willebrand disease implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to measure vWF collagen binding activity. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for bleeding disorder diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper collection can affect results. Inflammation may alter vWF activity.
Clinical Significance: Low vWF collagen binding confirms von Willebrand disease, guiding desmopressin or vWF replacement therapy. Normal levels may require other vWF tests.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: vWF antigen, vWF ristocetin cofactor, or factor VIII to confirm von Willebrand disease diagnosis.
Test Limitations: Non-specific for disease subtype; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH Hematology Guidelines, 2023; Blood, Favaloro EJ, 2022.
